ELISA/assay

人类n-myc原癌基因蛋白, MYCN酶联免疫吸附试剂盒

MBS904474

48-Strip-Wells

510美元

酶联免疫吸附试剂盒

人类n-myc原癌基因蛋白, MYCN酶联免疫吸附试剂盒

v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)

Human N-myc proto-oncogene protein (MYCN) ELISA kit; MODED; N-myc; NMYC; ODED; bHLHe37; N-myc proto-oncogene protein; neuroblastoma MYC oncogene; neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene; oncogene NMYC; pp65/67; v-myc avian; v-myc myelocytomatosis viral related oncogene; neuroblastoma derived (avian)

N-myc proto-oncogene protein isoform 1; N-myc proto-oncogene protein; N-myc proto-oncogene protein; pp65/67; oncogene NMYC; neuroblastoma MYC oncogene; class E basic helix-loop-helix protein 37; neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; Class E basic helix-loop-helix protein 37; bHLHe37

MYCN

MYCN;MYCN;NMYC;ODED;MODED;N-myc;bHLHe37;BHLHE37;NMYC;bHLHe37

MYCN_HUMAN

人类

464

This assay has high sensitivity and excellent specificity for detection of human MYCN. No significant cross-reactivity or interference between human MYCN and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates, Cell lysates. Assay Type: Sandwich. Detection Range: 15.6 pg/ml -1000 pg/ml. Sensitivity: The minimum detectable dose of human MYCN is typically less than 3.9 pg/ml. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for MYCN has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any MYCN present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for MYCN is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of MYCN bound in the initial step. The color development is stopped and the intensity of the color is measured.

19923312

NP_005369.2

NM_005378.5

P04198

49,561 Da

Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987)

This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2014]

N-Myc: a proto-oncogenic transcription factor. Plays a role in cell proliferation, apoptosis and in the development of human tumors. Protein type: Transcription factor; DNA-binding; Oncoprotein. Chromosomal Location of Human Ortholog: 2p24.3. Cellular Component: chromatin; nucleus. Molecular Function: protein dimerization activity; protein binding; DNA binding; transcription factor activity. Biological Process: regulation of transcription from RNA polymerase II promoter; branching morphogenesis of a tube; negative regulation of astrocyte differentiation; positive regulation of mesenchymal cell proliferation; positive regulation of transcription from RNA polymerase II promoter; embryonic digit morphogenesis; cartilage condensation; embryonic skeletal morphogenesis; lung development. Disease: Feingold Syndrome 1; Tracheoesophageal Fistula With Or Without Esophageal Atresia

48-Strip-Wells

510美元

96-Strip-Wells

725

5x96-Strip-Wells

2565

10x96-Strip-Wells

4800